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Abstract (245) 17 
Background – In January 2016, clinical TB guidance in the UK changed to no longer recommend 18 
screening contacts of non-pulmonary, non-laryngeal (ETB) index cases. However, no new evidence 19 
was cited for this change, and there is evidence that screening these contacts may be worthwhile. 20 
The objective of this study was to estimate the cost-effectiveness of screening contacts of adult ETB 21 
cases and adult pulmonary or laryngeal tuberculosis (PTB) cases in London, UK.  22 
Methods – We carried out a cross-sectional analysis of data collected on tuberculosis index cases 23 
and contacts in the London tuberculosis register, and an economic evaluation using a static model 24 
describing contact tracing outcomes. Incremental cost-effectiveness ratios (ICERs) were calculated 25 
using no screening as the baseline comparator. All adult TB cases (≥15 years old) in London from 26 
2012-15, and their contacts, were eligible (2465/5084 PTB and 2559/6090 ETB index cases were 27 
included).  28 
Results – Assuming each contact with PTB infects 1 person/month,  the ICER of screening contacts of 29 
ETB cases was £78000/QALY (95% CI: 39000 to 140000) and screening contacts of PTB cases was 30 
£30000/QALY (95% CI: 18000 to 50000). The ICER of screening contacts of ETB cases was 31 
£30000/QALY if each contact with PTB infects 3.4 people/month. Limitations of this study include 32 
the use of self-reported symptomatic periods, and lack of knowledge about onward transmission 33 
from PTB contacts. 34 
Conclusions –Screening contacts of ETB cases in London was almost certainly not cost-effective at 35 
any conventional willingness-to-pay threshold in England, supporting recent changes to NICE 36 
national guidelines.   37 
3 
 
Key Messages 38 
What is the key question? Was NICE correct to change its tuberculosis clinical guidelines to no 39 
longer recommend screening contacts of non-pulmonary TB cases? 40 
What is the bottom line?  It is almost certainly not cost-effective to screen contacts of non-41 
pulmonary TB cases in London at a willingness-to-pay-threshold of £30000/QALY, providing strong 42 
evidence that the decision to cease recommending screening contacts of non-pulmonary cases was 43 
the correct one. 44 
Why read on? In addition to helping an answer an important policy question that has been 45 
questioned by several recent papers, this article provides the first cost-effectiveness analysis of 46 
contact tracing in the UK and the first to incorporate non-pulmonary cases, and proposes a novel 47 
way to evaluate contact tracing effectiveness. 48 
  49 
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Introduction (542) 50 
Following four years of decline, the incidence of tuberculosis (TB) in England had fallen to 51 
10.2/100000 in 20161, but is still higher than most other countries in western and northern Europe2. 52 
Contact tracing, the systematic screening of contacts of cases , is a fundamental part of TB control in 53 
high-income countries, and is highlighted as a key element of the Public Health England 54 
(PHE)/National Health Service (NHS) England collaborative tuberculosis strategy 2015-20203. It is 55 
also used around the world for other infectious diseases, including Ebola4, meningococcal disease5 56 
and sexually transmitted infections6. The aim of contact tracing for TB is threefold: to reduce 57 
morbidity and mortality in contacts with TB by finding them sooner; to reduce transmission from 58 
those contacts with active TB; and to find contacts with latent M. tuberculosis infection (LTBI) who 59 
are eligible for preventive therapy (PT)7. 60 
In January 2016, the UK National Institute for Health & Care Excellence (NICE) TB guidelines changed 61 
from recommending screening contacts of all cases, to only screening contacts of pulmonary or 62 
laryngeal TB (PTB) cases. No new evidence was cited to justify this change8. Although the guidance 63 
on whether contacts of non-pulmonary, non-laryngeal cases (ETB) are screened differs between 64 
countries9,10, most advocate not screening contacts of these cases. Neither the CDC nor the WHO 65 
advocate screening contacts of these cases, although the WHO guidance is mainly aimed at low- and 66 
middle-income countries11,12.  67 
England has a high proportion of cases with non-pulmonary TB (51% in the most recent year), 68 
associated particularly with immigrants from the Indian subcontinent1,13. 69 
Whilst ETB cases are typically not infectious, there is evidence that their contacts are more likely to 70 
have TB than the general population. Between 2012-15, the prevalence of active TB amongst 71 
contacts of ETB index cases in London was 0.7%14, compared to 0.027% in the general population15. 72 
Similar patterns are observed in Birmingham16,17, and in both cities the prevalence of disease 73 
amongst contacts of ETB cases was higher than the prevalence of disease amongst migrants eligible 74 
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for pre-entry screening18 ,and more than 10 times higher than the NICE threshold for new entrant 75 
screening17. Additionally, studies have shown only 25% of pairs of cases sharing an address in the 76 
UK19, and 20% of case-contact pairs in London20 had different M. tuberculosis isolates, implying the 77 
risk of disease in household contacts is high irrespective of whether transmission has occurred. This 78 
suggests that the fact that ETB cases are not infectious may not be a valid justification for not 79 
screening their contacts.  80 
In light of this evidence, key stakeholders have questioned the change in guidance and a cost-81 
effectiveness analysis has been called for17. To our knowledge, only one previous study has 82 
attempted to evaluate the cost-effectiveness of contact tracing21, and no studies have done so in the 83 
UK or London, nor have any studies attempted to evaluate the cost-effectiveness of contact tracing 84 
delineated by site of disease of the index case. In this study we aim to evaluate the effectiveness and 85 
cost-effectiveness of contact tracing, for ETB and PTB index cases, in London. We first estimate 86 
symptomatic periods and the number of contacts found with active disease or LTBI per index case. 87 
We then use these values alongside previously published data to develop a simple static model to 88 
calculate the cost-effectiveness.   89 
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Methods (1177) 90 
Data analysis: We used data on adult and adolescent (> 15 years old) TB cases notified to the 91 
London TB register (LTBR) during 2012-2015. The LTBR is a web-based register containing 92 
demographic and clinical data on all TB cases notified in London since 200214. We excluded index 93 
cases that were notified in a region and year where the completeness was less than 80%, or were 94 
children (< 14 years old) (because contacts of children with ETB will still be screened under new 95 
guidelines)8. When estimating yield we excluded index cases who first accessed health-care through 96 
contact investigation, as the number of contacts is not recorded consistently14 . Further details of 97 
exclusions and the representativeness of data are discussed in Cavany et al(see table 1 in that paper 98 
in particular), but demographic characteristics were similar between included and excluded data14. 99 
Costs were calculated based on national accounting expenditures and current treatment guidance 100 
for England8,22 (see Appendix part 1 for details). Note that, in this manuscript, ETB refers exclusively 101 
to non-pulmonary, non-laryngeal TB, and so patients with pulmonary and/or laryngeal TB are 102 
classified in PTB, irrespective of whether they have involvement in other organs. 103 
Other data sources: Estimates of utility scores were taken from Jit et al23. The life-time risk of 104 
developing disease following infection was taken from Sloot et al.24 and the efficacy of PT from 105 
Smieja et al.25  and Ayieko et al.26  See Table 1 for details of data sources. 106 
Effectiveness: We quantified the effectiveness of contact tracing with four outcomes: 107 
1. Morbidity: the reduction in time contacts with TB are symptomatic if they are found earlier 108 
due to contact tracing. 109 
2. Prevention: the number of contacts with LTBI prevented from developing active TB following 110 
PT.  111 
3. Transmission: the number of cases prevented by reducing transmission from: a) contacts 112 
with prevalent TB found earlier through contact tracing; b) cases prevented from occurring 113 
due to PT.  114 
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4. Mortality: the number of TB deaths prevented by contact tracing. 115 
Model description: We developed a simple static model to estimate the cost-effectiveness of 116 
screening contacts of ETB and PTB cases in London during the period 2012-2015. The model was 117 
used to calculate the four measures of effectiveness and estimate the quality-adjusted life-years 118 
(QALYs) gained by contact tracing using the following equations (see Table 1 and Table 2 for 119 
definitions of symbols). 120 
In all equations 𝜎 is either 𝑃 or 𝐸, and represents the site of disease of the index cases under 121 
analysis. The number of PTB index cases is given by 𝑁𝑃 = (1 − 𝑓𝐸)𝑁 and the number of ETB index 122 
cases is given by 𝑁𝐸 = 𝑓𝐸𝑁, where 𝑓𝐸 is the fraction of all adult cases that have ETB. 123 
The reduction in morbidity was calculated using the number of contacts with TB per index case (𝑌𝜎), 124 
the proportion of contacts with TB that have ETB (𝜖𝜎) and the difference in symptomatic period of 125 
cases found through contact tracing and those found through other routes: 126 
𝑡morbidity, 𝜎 = 𝑁𝜎 (𝑌𝜎(1 − 𝜖𝜎) (
𝑆𝑃,passive − 𝑆𝑃,traced
365.25
) + 𝑌𝜎𝜖𝜎 (
𝑆𝐸,passive − 𝑆𝐸,traced
365.25
)) 127 
The number of cases of TB prevented by PT, assuming contacts with LTBI are recently infected is: 128 
𝑁prevention, 𝜎 = 𝑁𝜎 ( ∑ 𝑦𝜎𝜙𝜎,𝑗
𝑗=𝑎,𝑐
𝜃𝑗,𝜎,𝐵𝜃𝑗,𝜎,𝐶𝜏𝑗) 𝑃 129 
where 𝜙𝜎,𝑐 = 1 − 𝜙𝜎,𝑎. As the efficacy of PT is different in children (𝑐) and adults (𝑎), and children 130 
are more likely to begin preventive therapy than are adults (Appendix part2, Table G), we calculated 131 
the effectiveness of PT separately for these two groups. 132 
The number of cases of TB prevented by reducing transmission from contacts with PTB by finding 133 
them sooner is: 134 
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𝑁transmission, 𝜎 = 𝑁𝜎𝑌𝜎(1 − 𝜖𝜎) (
𝑆𝑃,passive − 𝑆𝑃,traced
365.25
) 𝑟𝑃 135 
The prevention of subsequent generations of TB cases which would have occurred in the absence of 136 
contact tracing is given by 𝑁later generations, 𝜎 (see Appendix part 3). 137 
The number of TB-related deaths prevented by screening contacts is calculated as follows: 138 
𝑁mortality, 𝜎 = (
365.25𝑡morbidity, 𝜎
𝑆overall
+ 𝑁transmission, 𝜎 + 𝑁prevention, 𝜎 + 𝑁later generations, 𝜎) 𝜇 139 
where 𝜇 is the case fatality ratio. The first term in this equation describes the reduction in mortality 140 
among prevalent cases in contacts identified sooner via contact tracing. 141 
To calculate the amount of onward transmission from prevented cases, we assumed a range of 142 
values for the number of new infections per PTB case per month infectious, 𝑟,  and explored the 143 
dependence of results on this parameter. This parameter, 𝑟, can be related to the updated Styblo 144 
rules developed by Trunz et al. and van Leth et al.27,28; these studies calculated that each case of 145 
smear positive TB would lead to approximately 3 to 6 new infections, equating to a value of 𝑟 146 
between 0.5 and 1 (see Appendix part 4).  147 
Cost-effectiveness:  Costs were calculated from a health system perspective. We excluded diagnostic 148 
and treatment costs of contacts with TB, as we assumed these contacts would be treated later 149 
regardless of whether the contact investigation took place. However, we subtracted the costs of 150 
diagnosis and treatment of cases that are prevented. We assumed latently infected contacts are 151 
given a 3 month course of rifampicin and isoniazid (with pyridoxine)8, and assumed this has the same 152 
efficacy as 6 months of isoniazid29. 153 
We calculated the resulting incremental cost-effectiveness ratio (ICER) for contact tracing of both 154 
PTB and ETB index cases, using no screening as the baseline comparator for both. Equations for 155 
these calculations are given in the Appendix part 3. Following NICE recommendations, we assumed a 156 
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an ICER greater than  £20000-30000/QALY was cost-effective30 – this is the threshold often used in 157 
NICE guidance to determine whether an intervention is cost-effective, and is also known as the 158 
“willingness-to-pay” threshold. We included secondary cases which occurred at any time after 159 
infection, but assumed most occur in the first year24. Consequently, most costs and QALY gains 160 
occurred in the first year, and so no discounting was included in the main analysis (see Appendix part 161 
5 for a discussion of discounting). 162 
Uncertainty and sensitivity: 95% confidence intervals were calculated by randomly selecting 10000 163 
parameter sets from the distributions shown in Table 1 and Table 2.  Correlation coefficients were 164 
calculated between the distribution of each parameter and distribution of the ICER. 165 
We explored the sensitivity to the symptomatic period by doubling each of these periods, and to 166 
assumptions about risk of disease following infection and preventive therapy by using estimates of 167 
these from Erkens et al.31 instead of the estimates from Sloot et al.24. 168 
We explored sensitivity to utility scores by using values from Mears et al.23. These were derived from 169 
the same source 32 as those of Jit et al.33 used in our primary analysis, but differ as the Jit et al values 170 
were based on London specific data. 171 
Additional analyses: We undertook an additional analysis to estimate the cost-effectiveness of 172 
screening of ETB cases that have pleural TB, because it has been reported that 55% of patients with 173 
pleural involvement according to X-ray are culture positive on induced sputum34. We also examined 174 
whether there were differences in the cost-effectiveness of screening contacts of UK-born and non-175 
UK born ETB cases, due to the large differences in the proportion of cases that are ETB between 176 
these two groups (51.4% vs 31.9% respectively1. 177 
Role of finding source: The funding sources played no part in the study design, data analysis, writing 178 
of the manuscript or decision to submit for publication.  179 
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Results (951) 180 
Mean symptomatic periods. During the period 2012-2015 in London, there were 5084 PTB cases, of 181 
whom 2465 met the inclusion criteria and had data on symptomatic period. Of these, 82 were found 182 
through contact tracing, and were symptomatic for a mean period of 76.6 days (95% CI: 58.5, 94.7). 183 
Those who accessed care through other routes were symptomatic for a longer mean period of 110 184 
days (95% CI: 103, 117 days) (p=0.0016) (Table 2) 185 
During the same period there were 6090 ETB cases, of whom 2559 were included and had data on 186 
symptomatic period. Of these, 26 were found through contact tracing and had a mean symptomatic 187 
period of 152 days (95% CI: 15.0, 289 days). Those who accessed care through other routes had a 188 
mean symptomatic period of 180 days (95% CI: 165, 195 days) (p=0.36). See Table E in Appendix part 189 
2 for further details. 190 
Preventive therapy. Of 1497 contacts with LTBI identified in the study period, 1165 (77.8% (95% CI: 191 
74.9%, 80.7%) started PT and 918 of those that started (78.6% (95% CI: 75.4%, 81.8%) completed PT 192 
(Table 2). See Table G in Appendix part 2 for further details; of note is that children are much more 193 
likely than adults to start PT and, for contacts of PTB cases, to complete PT. 194 
Effectiveness  195 
Reduction in morbidity of contacts: On average, in a single year, not screening contacts of adult ETB 196 
cases would have led to those contacts with TB being undiagnosed for a combined additional 2.58 197 
years (95% CI: 0.660 to 8.59) (Table 3). For contacts of PTB cases this would be 10.5 years (95% CI: 198 
4.02 to 26.4). 199 
Cases prevented by preventive therapy: By giving PT to contacts of ETB cases we would expect to 200 
prevent 5.45 (95% CI: 3.71 to 7.59) cases. This value would be 18.9 (95% CI: 13.1 to 25.8) cases 201 
prevented by giving PT to contacts of PTB index cases.  202 
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Cases prevented by reduced transmission from contacts: Finding contacts of ETB index cases with TB 203 
sooner via contact tracing, thereby reducing onward transmission, could prevent 1.71 cases (95% CI: 204 
0.584 to 3.33) when 𝑟 = 1 new infections per PTB case per month infectious. The corresponding 205 
value for PTB index cases is 8.76 (95% CI: 3.56 to 14.9). This reduction in cases is directly 206 
proportional to the assumed value of 𝑟.  207 
Prevention of subsequent generations of cases: Preventing cases from occurring amongst contacts of 208 
contacts of ETB cases could avert 1.62 cases (95% CI: 0.772 to 3.11) when 𝑟 = 1, and 5.19 cases (95% 209 
CI: 2.08 to 12.2) when 𝑟 = 2. The corresponding figures for PTB index cases are 8.63 (95% CI: 4.77 to 210 
14.7) and 33.1 (95% CI: 16.1 to 66.7). 211 
Reduction in mortality: When 𝑟 = 1, screening contacts of ETB cases could prevent 0.551 deaths 212 
(95% CI: 0.303 to 1.14) and screening contacts of PTB cases 2.27 deaths (95% CI: 1.36 to 3.94). 213 
Cost-effectiveness: The cost per QALY of screening the contacts of ETB cases is £101000/QALY (95% 214 
CI: 46200 to 178000) when transmission is not included (𝑟 = 0), £77700/QALY (95% CI: 38800 to 215 
139000) for 𝑟 = 1 new infection per PTB case per month infectious and £56400/QALY (95% CI: 216 
29300 to 102000) for 𝑟 = 2 (Table 3, Figure 1a). The equivalent values for PTB cases are 217 
£43700/QALY (95% CI: 23700 to 70100), £30300/QALY (95% CI: 17700 to 50100) and £18700/QALY 218 
(95% CI: 10500 to 32700) respectively (Figure 1b). Screening contacts of ETB cases becomes cost-219 
effective at a £30000/QALY threshold when 𝑟 = 3.40. If 𝑟 = 1,  the yield of ETB index cases would 220 
need to be  0.0959 (an almost 5-fold increase above the observed yield, and greater than current 221 
PTB yield) in order for screening contacts of ETB cases to become cost-effective at £30000/QALY. 222 
Sensitivity: Cost-effectiveness results are most sensitive to the symptomatic period of those found 223 
through contact tracing (Appendix table H) (especially of contacts of ETB index cases), the probability 224 
of developing disease, and the yield of ETB index cases. At low levels of transmission from PTB 225 
contacts, the symptomatic period of contacts with ETB explains most of the variation in the ICER. As 226 
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the number of infections generated by contacts is increased, the results become more sensitive to 227 
the probability of developing disease and the symptomatic period of PTB index cases, and less 228 
sensitive to the symptomatic period of ETB index cases. Increasing each symptomatic period by a 229 
factor of 2 (Figure 1c and d), then for 𝑟 ≥ 1.60 the mean cost-effectiveness of screening contacts of 230 
ETB cases is below the £30000/QALY threshold. Calculating the probability of developing disease 231 
from Erkens et al. rather than Sloot et al. does not qualitatively change the cost-effectiveness results 232 
(not shown). Using utility scores used by Mears et al.23 instead of those used by Jit et al.33 leads to a 233 
slight decrease in cost-effectiveness (Appendix part 6). 234 
Additional analyses: While screening contacts of pleural TB cases is more cost-effective than 235 
screening contacts of other ETB cases, it still appears to be probably not cost-effective at a threshold 236 
of £30000/QALY for values of 𝑟 less than 3 (Appendix figure B).  237 
Similarly, If we restrict our analysis to UK-born cases only, then screening contacts of ETB cases is 238 
probably not cost-effective at a threshold of £30000/QALY  for values of 𝑟 below 3 (Appendix figure 239 
C).  It is also unlikely to be cost-effective to screen contacts of non-UK born ETB cases for values of r 240 
below 4. For PTB cases, it is probably cost-effective to screen contacts of non-UK born PTB cases at a 241 
threshold of £30000/QALY when r is greater than 1.65 (Appendix figure C). Screening contacts of UK 242 
born PTB cases is probably cost-effective at £30000/QALY even if no transmission takes place, and 243 
becomes probably cost-effective at £20000/QALY when r is greater than 0.834.  244 
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Discussion (1627) 245 
Principal findings:   246 
On average, we estimate that in a single year, screening contacts of ETB would save a total of 2.58 247 
years of morbidity in contacts with prevalent TB, and prevent at least 5.45 cases through reduced 248 
transmission and PT. However, screening ETB contacts was very unlikely to be cost-effective at a 249 
threshold of £30000/QALY, even with the assumption of high levels of transmission from contacts. 250 
Hence, the results presented here support recent changes to the NICE guidelines to remove 251 
screening of contacts of ETB cases from their guidance. In contrast, screening contacts of PTB cases 252 
was probably cost effective at a £30000/QALY threshold, especially when assuming high levels of 253 
transmission from contacts. Neither was likely to be cost-effective at a £20000/QALY threshold at 254 
plausible levels of transmission. 255 
Strengths and limitations:  256 
This study used high quality data on contact tracing yield in London to answer an important question 257 
for TB care and prevention, which has implications for TB policy in the UK. The approach used 258 
proposes a novel way of quantifying the effectiveness of contact tracing across four potential 259 
impacts (reduced morbidity, preventive therapy, reduced transmission and reduced mortality). The 260 
main limitation of the study is the large uncertainty in several parameters. However, we explored 261 
this first by varying the number of infections generated by each case (𝑟), and by carrying out a 262 
probabilistic sensitivity analysis of all other parameters. A related limitation is the treatment of 263 
transmission. It is difficult to know the rate at which infectious contacts would infect further 264 
contacts, so we explored a range of assumptions. We did not characterise the indirect effect of 265 
contact tracing on transmission at a population level, though as only five percent of all cases in 266 
London are found through contact tracing, this is probably negligible over short time-scales. The 267 
quantitative nature of this approach is unable to assess broader outcomes of contact tracing, such as 268 
community engagement and tackling stigma. Finally, we used the self-reported symptomatic period 269 
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to estimate the time during which cases are infectious. Due to issues with patient recall and the fact 270 
that the ratio of estimated prevalence to incidence in London15,35 is much greater than the mean 271 
self-reported symptomatic period found in this study, it is likely that this value systematically 272 
underestimates the true time people are symptomatic. Our sensitivity analysis showed that cost-273 
effectiveness of contact tracing would increase and screening contacts of ETB cases would be 274 
possibly cost-effective at a £30000/QALY threshold if the symptomatic period was double that 275 
estimated by self-reported symptom onset (Figure 1c and d).  276 
Our approach should not suffer from selection bias as, although we only included those cases and 277 
contacts detected by healthcare, in this case we are interested in the actual effect that would be 278 
experienced by the healthcare system, and so we are only interested in those cases and contacts 279 
that are actually found. Whilst we did exclude some regions and time-periods from the underlying 280 
dataset due to large amounts of missing data (see Cavany et al for details14), meaning some 281 
ascertainment bias may have been present, the excluded cases had similar demographic 282 
characteristics to those included. It is also possible some differential bias may have been present if 283 
cases were incorrectly classified as ETB or PTB, which is possible as a 24% of PTB cases and 51.9% of 284 
extrapulmonary cases were not culture confirmed in 2017 in England1. 285 
Relation to other studies:  286 
In recent years, studies in the UK have evaluated the cost-effectiveness of screening new migrants36 287 
and hard to reach populations using a mobile X-ray unit (MXU, known as Find & Treat)33. In 2011 288 
Pareek et al.36 found that screening migrants from countries with an incidence exceeding 289 
150/100000 cost £21000 per case averted. This is cheaper than screening ETB contacts, and similar 290 
to screening  PTB contacts for 𝑟 = 1 new infections per PTB case per month infectious (Table 3). Jit 291 
et al. found that screening hard-to-reach groups in London cost £6400-£10000/QALY gained, so was 292 
more cost-effective than screening PTB cases even if 𝑟 = 2. In their study, Jit et al.33 found that 293 
about 80% of QALYs gained were due to improved case-management of these complex cases, and 294 
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the cost-effectiveness of screening alone was similar to screening contacts of PTB cases. The case 295 
management impact would likely be smaller for contact tracing than for the MXU, because the 296 
population of contacts is less complex, and case management is not an explicit aim of contact 297 
tracing. When Dasgupta et al.21 compared the cost-effectiveness of screening close contacts to 298 
migrant screening in Montreal, they found that close contact investigation was cost saving. This was 299 
due to much lower treatment costs of contacts as opposed to cases found through other routes, due 300 
largely to much higher rates of hospitalization amongst passively detected cases. However, this 301 
assumption was based on only six cases found through contact tracing. We did not explore the 302 
impact of decreased hospitalization rates here due to a lack of data. Finally, a 2008 study in British 303 
Columbia, Canada37 found that giving PT to contacts was cost-effective, though this study focused on 304 
infectious index cases. Our results are not directly comparable with this study due to its focus on PT, 305 
but both support the continued screening of contacts of PTB cases. 306 
Interpretation of results:   307 
These results support the recent decision to remove screening contacts of adult ETB cases from NICE 308 
guidance. In order for screening these contacts to be cost-effective at a £30000/QALY threshold, 𝑟 309 
would need to be 3.40 new infections per PTB case per month infectious, which would mean each 310 
smear positive case would need to generate 21 new infections. This is likely to be high for some 311 
settings27, but may be plausible in crowded environments, such as homeless shelters38. Additionally, 312 
we found that if the yield per ETB index case was above 0.0959, then the ICER for screening contacts 313 
of these cases was below £30000/QALY. In London, ETB cases with a history of homelessness or drug 314 
use have a yield greater than this (unpublished data), supporting recommendations for active case-315 
finding amongst this group. Additionally, subgroups for whom the yield is higher, are also those for 316 
whom 𝑟 is likely to be higher, further increasing the impact of screening contacts of those 317 
subgroups. It is unlikely that the average yield of ETB cases in other parts of the UK are much higher 318 
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than those seen in London16, implying that it would also not be cost-effective to screen contacts of 319 
ETB cases nationally.  320 
If we stratify our data into UK born and non-UK born groups, we see that it is more cost-effective to 321 
screen contacts of UK born PTB cases than it is non-UK born PTB cases (Appendix figure C). This is in 322 
part due to the much greater difference in symptomatic period between those found through 323 
contact tracing and those found through other routes for UK born cases compared to non-UK born 324 
cases (Appendix table M and N). This implies the gap in cost-effectiveness of contact tracing for UK 325 
born cases compared to non-UK born cases could be closed if contact tracing found non-UK born 326 
cases more quickly. The caveat to this result is that there is an assumption that contacts of UK born 327 
cases are also UK born, and non-UK born cases are non-UK born, which is not true, and which means 328 
we underestimate the impact of contact screening for non-UK born cases. 329 
The impact on the ICER caused by changing the amount of transmission (𝑟) indicates the importance 330 
of reducing transmission from contacts as one of the impacts of contact tracing. It is plausible, 331 
though, that the number of infections generated by a contact with PTB (i.e. the value of 𝑟) will be 332 
lower than that suggested by the re-estimated  Styblo rule27,28, as the household contacts of 333 
someone themselves found through contact tracing are more likely to have already been infected.  334 
The main reason for the low ICER for ETB index cases was the small difference in symptomatic period 335 
of contacts with ETB and cases with ETB found through other routes (Appendix table H), suggesting 336 
that the impact may be improved by hastening contact tracing for these contacts. The NICE 337 
guidelines now recommend PT for anyone aged under 65 years. This may cause a small 338 
improvement in cost-effectiveness, as we would now expect a higher yield of LTBI per case, as more 339 
contacts will be tested for LTBI, provided it is not accompanied by lower rates of PT enrolment and 340 
completion. The introduction in 2017 of whole genome sequencing (WGS) in the UK39 may also 341 
affect our conclusions. Whilst a study of the current strain typing service found no impact on contact 342 
17 
 
tracing23, it is plausible that faster turnaround times and improved targeting available with WGS may 343 
affect contact tracing yields.  344 
Further research:  345 
This work would benefit from an improved understanding of the rate of onward transmission from 346 
contacts. Mathematical modelling work incorporating transmission on a network structure may help 347 
to understand this. It would also help to have a greater understanding of the proportion of contacts 348 
that have pulmonary TB and how this differs across groups. If there are subgroups for whom a 349 
greater than average proportion of contacts with TB have PTB, then this would increase the cost-350 
effectiveness in these groups. Whilst we were able to estimate this proportion for the whole 351 
population, our small sample meant we could not stratify this estimate. Work to understand how 352 
the different screening approaches (migrant, hard-to-reach populations and contacts) interact would 353 
help our understanding of the impact of each. Our results were very sensitive to estimates of the 354 
symptomatic period of contacts, both due to the uncertainty of these estimates and the fact that 355 
they are based on self-reported periods. A more thorough understanding of diagnostic delay 356 
amongst both contacts and non-contacts is needed.357 
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Tables 358 
Table 1: Variables and constants from other sources. CI = confidence interval, ETB = non-pulmonary and non-laryngeal tuberculosis, LTBR = London TB register, NICE = National Institute 359 
for Health & Care Excellence, PT = preventive therapy, TB = tuberculosis, BNF = British National Formulary, QALY = quality-adjusted life years, UK = United Kingdom. †=this was calculated 360 
using the age-specific case-fatality ratios given in Mears et al. and the age-structure of cases calculated from the LTBR. Note that some confidence intervals differ slightly from those in the 361 
literature due to the use of beta distributions. Following current treatment guidance (NICE 2016), we used the following references to calculate cost values: NICE 2011, Pareek et al. 2011, 362 
Reference costs 2016, Dowdy et al. 2008, Dinnes et al. 2007, BNF 2017; where necessary, we inflated costs according to inflation to the base year 2016. See Appendix parts 1 and 6 for 363 
details of cost and utility calculations. 364 
Name of variable (units, if applicable)  Symbol Value 95% CI, (or *range) Distribution Source 
Life-time probability of developing disease 
following infection 
𝑃 0.1 (0.08, 0.12) Beta Sloot et al.24 
Efficacy PT in adults 
  
𝜏𝑎 0.6 (0.49, 0.70) Beta Smieja et al.
25 
Efficacy PT in children 
 
𝜏𝑐 0.4 (0.16, 0.57) Beta Ayieko et al.
26 
Average number of cases per year 
 
𝑁 2790 N/a N/a LTBR 
Fraction of all adult cases that have ETB 
 
𝑓𝐸 0.545 N/a N/a LTBR 
Fraction of those tested for active TB that 
have active TB 
𝑓𝑐 0.2 N/a N/a Mears et al.
23 
Case fatality ratio 
 
𝜇 0.0363 N/a N/a Mears et al.23†and LTBR 
Relative average treatment length of non-
completed PT 
𝑓𝑖 0.33 N/a N/a Assumption 
Contact tracing, per contact traced, £ 
 
𝐶0 244 N/a N/a See Appendix part 1 
Further tests if case is suspected to have 
active disease, £ 
𝐶1 497 N/a N/a See Appendix part 1 
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Cost per full course PT (3 month rifampicin 
and isoniazid, with pyridoxine), £ 
𝐶PT 852 N/a N/a See Appendix part 1 
Cost per full course (6 months) of 
treatment of tuberculosis disease, £ 
𝐶FT 1694 N/a N/a See Appendix part 1 
Average utility of a healthy person, given 
age structure of TB cases in London 
𝑈𝐻 0.876 N/a N/a Calculated from Kruijshaar et al via Mears et al 
Symptom onset to diagnosis 𝑈0 0.68𝑈𝐻 N/a N/a Kruijshaar et al via Jit et al 
On treatment 𝑈1 0.79𝑈𝐻 N/a N/a Kruijshaar et al via Jit et al 
Utility preventive therapy 𝑈PT 0.9992𝑈𝐻 N/a N/a Kruijshaar et al via Mears et al 
Average # of QALYs at death for someone 
living in UK 
𝐴𝐻 72.6 N/a N/a Calculated from Mears et al. and LTBR 
Average # of QALYs at death for someone 
living in UK with TB as cause of death 
𝐴𝑇𝐵 52.2 N/a N/a Calculated from Mears et al. and LTBR 
  365 
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Table 2: Estimates of parameters calculated from the LTBR. All parameters are chosen from a normal distribution. ETB = non-pulmonary and non-laryngeal tuberculosis, PTB=Pulmonary 366 
or laryngeal tuberculosis. LTBI = latent M.Tb infection, LTBR = London TB report, PT = preventive therapy, TB = tuberculosis 367 
Name of variable (units, if applicable)  Index case 
disease type 
Symbol Value 95% Confidence intervals 
Number of contacts screened per index case   
      
ETB 𝑛𝐸 2.50 [2.41, 2.59] 
PTB 𝑛𝑃 3.86 [3.72, 4.00] 
Number of contacts found with TB per index case ETB 𝑌𝐸 0.0196 [0.0119, 0.0273] 
PTB 𝑌𝑃 0.0938 [0.0774, 0.110] 
Proportion of contacts with TB that have ETB ETB 𝜖𝐸 0.486 [0.329, 0.643] 
PTB 𝜖𝑃 0.337 [0.278, 0.396] 
Number of contacts found with LTBI per index case ETB 𝑦𝐸  0.119 [0.104, 0.134] 
PTB 𝑦𝑃 0.471 [0.428, 0.514] 
Proportion of index contact’s with LTBI that are children ETB 𝜙𝐸,𝑐 0.206 Not varied 
PTB 𝜙𝑃,𝑐 0.360 Not varied 
Proportion of contacts with LTBI that begin PT, adult contact ETB 𝜃𝑎,𝐸,𝐵 0.611 [0.510, 0.712] 
PTB 𝜃𝑎,𝑃,𝐵 0.666 [0.604, 0.728] 
Proportion of contacts with LTBI that begin PT, child contact ETB 𝜃𝑐,𝐸,𝐵 0.931 [0.838, 1.02] 
PTB 𝜃𝑐,𝑃,𝐵 0.969 [0.922, 1.02] 
Proportion of contacts starting PT that complete PT, adult contact ETB 𝜃𝑎,𝐸,𝐶 0.875 [0.793, 0.957] 
PTB 𝜃𝑎,𝑃,𝐶  0.803 [0.742, 0.864] 
Proportion of contacts starting PT that complete PT, child contact ETB 𝜃𝑐,𝐸,𝐶  0.81 [0.638, 0.982] 
PTB 𝜃𝑐,𝑃,𝐶 0.906 [0.845, 0.967] 
Mean symptomatic period of PTB cases not found through contact tracing (days) N/a 𝑆𝑃,passive 110 [103, 117] 
Mean symptomatic period of PTB cases found through contact tracing (days) N/a 𝑆𝑃,traced 76.6 [58.5, 94.7] 
Mean symptomatic period of PTB cases (days)  N/a 𝑆𝑃,overall 109 [102, 116] 
Mean symptomatic period of ETB cases not found through contact tracing (days) N/a 𝑆𝐸,passive 181 [166, 196] 
Mean symptomatic period of ETB cases found through contact tracing (days) N/a 𝑆𝐸,traced 152 [15.0, 289] 
Mean symptomatic period of all cases (days) N/a 𝑆overall 147 [139, 155] 
21 
 
  368 
22 
 
Table 3: Summary of the effectiveness measures included, costs incurred, quality adjusted life years(QALYs)  gained and resulting incremental cost effectiveness ratio (ICER) for screening 369 
contacts of the indicated index cases compared to a baseline of not screening those contacts. Numbers are given for a year with a case-load that is the average caseload of the years 2012-370 
15 (i.e. 2790 cases); note that the case-load does not affect the ICER. No discounting was applied; see Appendix part 5 for a discussion of discounting. Case-equivalents averted refers to 371 
both cases averted, and the reduction in the time contacts are symptomatic divided by the mean symptomatic period of TB cases.  ETB = non-pulmonary, non-laryngeal; PTB = pulmonary 372 
or laryngeal; 𝒓 = the number of infections generated by a pulmonary contact per month infectious; ICER = incremental cost-effectiveness ratio; PT = preventive therapy (3 months of 373 
isoniazid and rifampicin). Numbers in brackets indicate the 95% confidence intervals.  374 
Quantity (units, if applicable) 
ETB indexes PTB indexes 
𝑟 = 0 𝑟 = 1 𝑟 = 2 𝑟 = 0 𝑟 = 1 𝑟 = 2 
Reduction in time contacts are 
symptomatic (years) 2.58 [0.66, 8.59] 2.58 [0.66, 8.59] 2.58 [0.66, 8.59] 10.5 [4.02, 26.4] 10.5 [4.02, 26.4] 10.5 [4.02, 26.4] 
Cases prevented by 
administering PT (cases) 5.45 [3.71, 7.59] 5.45 [3.71, 7.59] 5.45 [3.71, 7.59] 18.9 [13.1, 25.8] 18.9 [13.1, 25.8] 18.9 [13.1, 25.8] 
Transmission reduced by 
finding contacts sooner (cases) 0.0 [0.0, 0.0] 1.71 [0.584, 3.33] 3.41 [1.17, 6.62] 0.0 [0.0, 0.0] 8.76 [3.56, 14.9] 17.5 [7.02, 29.8] 
Transmission reduced from 
prevented cases (cases) 0.0 [0.0, 0.0] 1.62 [0.772, 3.11] 5.19 [2.08, 12.2] 0.0 [0.0, 0.0] 8.63 [4.77, 14.7] 33.1 [16.1, 66.7] 
Reduction in mortality 
(deaths) 
0.431 [0.238, 
0.977] 
0.551 [0.303, 
1.14] 
0.743 [0.408, 
1.45] 1.64 [0.997, 3.08] 2.27 [1.36, 3.94] 3.47 [2.04, 5.89] 
Total case-equivalents averted 
 11.9 [6.56, 26.9] 15.2 [8.34, 31.4] 20.5 [11.2, 39.9] 45.0 [27.5, 85.0] 62.4 [37.5, 109.0] 95.6 [56.2, 162.0] 
Total QALYs gained 
 10.6 [5.98, 23.4] 13.7 [7.66, 27.6] 18.7 [10.4, 35.6] 39.9 [24.8, 73.9] 56.3 [34.2, 95.9] 87.5 [51.7, 148.0] 
Total costs incurred  
(£ 000 000s) 1.07 [1.03, 1.12] 1.06 [1.02, 1.11] 1.05 [1.01, 1.1] 1.74 [1.67, 1.82] 1.71 [1.63, 1.78] 1.63 [1.52, 1.72] 
Incremental cost-effectiveness 
ratio (£ 000s/QALY) 
101.0 [46.2, 
178.0] 77.7 [38.8, 139.0] 56.4 [29.3, 102.0] 43.7 [23.7, 70.1] 30.3 [17.7, 50.1] 18.7 [10.5, 32.7] 
Probability the ICER is less 
than £30000/QALY 0.09% 0.260% 3.08% 14.8% 54.0% 95.6% 
Probability the ICER is less 
than £20000/QALY 0.00% 0.01% 0.02% 0.42% 7.26% 64.7% 
Threshold which the ICER is 
80% probable to be below (£ 
000s/QALY) 135 99.6 71.9 54.0 36.6 22.9 
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Figure caption 375 
Figure 1: Summary of incremental cost-effectiveness ratios and 95% confidence intervals (shaded region) for different 376 
levels of transmission from contacts. The comparator is no screening. The dashed horizontal line indicates the 377 
£30000/QALY cost-effectiveness threshold and the dotted horizontal line the £20000/QALY threshold. The solid 378 
horizontal line indicates when contact tracing becomes cost-saving. (a) and (b) represent the main results for ETB and 379 
PTB index cases respectively. (c) and (d) represent results for a symptomatic period which is double the self-reported 380 
period. GBP = pounds sterling, ETB = non-pulmonary, non-laryngeal tuberculosis, PTB = pulmonary or laryngeal 381 
tuberculosis, QALY = quality-adjusted life years, ICER = incremental cost-effectiveness ratio.382 
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